Tenaya Therapeutics, Inc.

Listed Company

TNYACIK 0001858848NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-90.60M

Total Assets

$146.92M

Equity

$123.27M

Shares Out

217.00M

Op. Cash Flow

$-68.26M

TNYA$0.81−6.10% · past yearDBEQ Basic

Daily closing prices

Business

Tenaya Therapeutics is a clinical-stage biotechnology company developing precision medicines for genetic heart disease. Its lead programs are AAV9-based gene therapies TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, both in Phase 1b/2 trials, plus TN-301, a selective HDAC6 inhibitor small molecule in Phase 1 development for heart failure with preserved ejection fraction. Tenaya operates as a fully integrated biopharmaceutical company with proprietary capabilities in target discovery, capsid engineering, promoter design, and AAV manufacturing.

Summary from 10-K filed 2026-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	69	87	98	95	54
General and administrative	25	29	33	31	18
Total operating expenses	93	116	131	126	73
Loss from operations	−93	−116	−131	−126	−73
Interest income	3	5	7	2	108,000
Other income, net	52,000	82,000	53,000	2,000	−23,000
Total other income, net	3	5	7	2	85,000
Net loss before income tax expense	−91	−111	−124	−124	−73
Net loss	−91	−111	−124	−124	−73
Net unrealized (loss) gain on marketable securities	−28,000	134,000	272,000	−237,000	−141,000
Comprehensive loss	−91	−111	−124	−124	−73
Net loss per share, basic	−0.59	−1.31	−1.68	−2.76	−4.1
Net loss per share, diluted	−0.59	−1.31	−1.68	−2.76	−4.1
Weighted-average shares used in computing net loss per share, basic	153	85	74	45	18
Weighted-average shares used in computing net loss per share, diluted	153	85	74	45	18

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	101	4	46	95	38
Short-term investments in marketable securities	—	57	59	91	213
Prepaid expenses and other current assets	5	6	7	7	4
Total current assets	106	67	112	194	255
Property and equipment, net	28	36	43	51	43
Operating lease right-of-use assets	9	12	10	12	12
Other noncurrent assets	4	5	6	5	4
Total assets	147	120	171	279	314
Accounts payable	4	5	6	10	11
Accrued and other current liabilities	9	8	13	11	9
Operating lease liabilities, current	3	3	4	4	2
Total current liabilities	15	16	23	24	22
Operating lease liabilities, noncurrent	8	11	8	11	14
Other noncurrent liabilities	410,000	281,000	253,000	228,000	182,000
Total liabilities	24	27	31	36	36
Commitments and contingencies (Note 4)	—	—	—	—	—
Preferred stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and 2024; 216,760,283 and 86,542,340 shares issued and outstanding as of December 31, 2025 and 2024	21,000	8,000	7,000	7,000	4,000
Additional paid-in capital	728	607	543	523	434
Accumulated other comprehensive income	0	28,000	−106,000	−378,000	−141,000
Accumulated deficit	−605	−514	−403	−279	−156
Total stockholders' equity	123	93	139	243	279
Total liabilities and stockholders' equity	147	120	171	279	314

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−91	−111	−124	−124	−73
Depreciation and amortization	8	8	9	6	3
Amortization (accretion) of premium (discount) on marketable securities	411,000	−184,000	315,000	−307,000	131,000
Stock-based compensation	13	17	15	11	3
Non-cash operating lease expense	2	3	3	2	1
Other	423,000	383,000	217,000	217,000	61,000
Prepaid expenses and other current assets	547,000	857,000	101,000	−3	−3
Other noncurrent assets	571,000	656,000	−601,000	−815,000	−3
Accounts payable	−1	−581,000	−3	2	9
Accrued and other current liabilities	532,000	−5	2	4	3
Operating lease liabilities	−3	−4	−4	−3	−1
Other noncurrent liabilities	102,000	0	1,000	−1,000	163,000
Net cash used in operating activities	−68	−91	−102	−104	−61
Purchases of property and equipment	−618,000	−1	−1	−21	−25
Purchases of marketable securities	0	−87	−57	−140	−213
Proceeds from sales of marketable securities	11	8	—	—	—
Proceeds from maturities of marketable securities	46	81	107	245	—
Other	0	17,000	−25,000	8,000	—
Net cash provided by investing activities	56	1	49	84	−239
Proceeds from exercise of stock options and employee stock purchase plan	139,000	979,000	682,000	380,000	374,000
Proceeds from exercise of warrants	2	0	—	—	—
Proceeds from exercises of pre-funded warrants	0	8,000	—	—	—
Net cash provided by financing activities	108	48	4	78	209
Net change in cash, cash equivalents and restricted cash	96	−42	−49	57	−90
Property and equipment included in accounts payable and accrued and other current liabilities	60,000	358,000	249,000	549,000	4
Offering cost included in accounts payable and accrued expenses and other current liabilities	415,000	0	—	—	—
Issuance of warrant in connection with Loan Agreement	0	175,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Tenaya Therapeutics, Inc.'s CIK number?

Tenaya Therapeutics, Inc.'s SEC CIK number is 0001858848 (1858848). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Tenaya Therapeutics, Inc.'s SEC filings?

All of Tenaya Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Tenaya Therapeutics, Inc. last report earnings?

Tenaya Therapeutics, Inc. (TNYA) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-208975). This is Tenaya Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Tenaya Therapeutics, Inc.'s most recent earnings 8-K?

Tenaya Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-208975. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Tenaya Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →